Form D · Biotechnology
Immunomic Therapeutics, Inc.
Rockville, MD · CIK 0001543256
Offering snapshot reported Jun 2, 2025 · SEC filing
- Reported sold
- $6.5M Offering amount: $16M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 29, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 2, 2025 | Initial | $6,500,000 | No comparison | 1 | SEC filing |
| Apr 10, 2024 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| Jan 14, 2021 | Amendment | $77,728,230 | $67,728,230vs Feb 26, 2020 | 6 | SEC filing |
| Feb 26, 2020 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Aug 3, 2018 | Initial | $314,500 | No comparison | 1 | SEC filing |
| Mar 15, 2017 | Initial | $4,629,750 | No comparison | 47 | SEC filing |
| Oct 15, 2014 | Amendment | $6,755,052 | $5,726,052vs Apr 24, 2014 | 56 | SEC filing |
| Oct 15, 2014 | Amendment | $6,755,052 | $0vs Oct 15, 2014 | 56 | SEC filing |
| Apr 24, 2014 | Initial | $1,029,000 | No comparison | 10 | SEC filing |
| Jun 12, 2013 | Amendment | $1,617,000 | $515,740vs Mar 5, 2012 | 60 | SEC filing |
| Jun 12, 2013 | Initial | $1,117,500 | No comparison | 30 | SEC filing |
| Jun 12, 2013 | Initial | $2,729,500 | No comparison | 36 | SEC filing |
| Mar 5, 2012 | Initial | $1,101,260 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-547820
Source: Form D, filed Jun 2, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Ahlgren | Director |
| Ki Hong Ahn | Director |
| Matthew Chang | Director |
| William G. Hearl | Director, Executive |
| Teri Jones Heiland | Executive |
| Hyuk Joo Jee | Director |
| Yang Gon Jin | Director |
| Dong Gun Kim | Director, Executive |
| Alex S Kim | Director |
| Michael Lack | Director |
| Winston I Lowe | Executive |
| Bruce F. Mackler | Director, Executive |
| William Barry Mcdonald | Director |
| William Barry Mc Donald | Director |
| Arlo Mcginn | Director |
| Steve Park | Director |
| Bernard C. Rudnick | Director, Executive |
| Lisa Salley | Executive |
| Ronald Thiboutot | Director |
| C. Eric Winzer | Executive |
| James Wishart | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Attn: Erin Duffy, 15010 Broschart Rd. Suite 250
Rockville, MD, 20850
Rockville, MD, 20850